Prestige BioPharma Completes Vaccine Center "Annual Production of 2.6 Billion Doses"

Completion of Chungbuk Osong Vaccine Center in 8 Months

Prestige Bio Pharma Group Vaccine Center Exterior View

[Asia Economy Reporter Cha Min-young] Prestige BioPharma, a pharmaceutical company specializing in antibody biopharmaceuticals, announced on the 1st that it has completed a vaccine center in Osong, Chungbuk. It took eight months since construction began in March this year.

The vaccine center, built using the patented ALITA smart bio factory construction method, is a six-story building with a total floor area of 13,42.88㎡. It is designed with an independent suite air conditioning system that significantly reduces the risk of cross-contamination even when producing various types of vaccines simultaneously.

The annual vaccine production capacity is 104,000 liters. The company can produce about 2.6 billion doses (single vaccination units) annually of the Russian novel coronavirus (COVID-19) vaccine 'Sputnik V', which it will manufacture under contract using the introduced technology, for first-dose vaccinations.

Based on the patented technology of its affiliate Prestige BioLogics, the center is designed to minimize cross-contamination risks even when producing multiple types of vaccines simultaneously. The flexibility of the facilities also enhances productivity.

Prestige BioPharma plans to expand its production scope not only to adenovirus vector vaccines like the Sputnik V vaccine but also to messenger RNA (mRNA) vaccines.

Park So-yeon, CEO of Prestige BioPharma, said, "The Prestige BioPharma Group vaccine center will be a solid base camp for the vaccine business we entered this year," adding, "All employees will strive to develop various vaccines here that save lives and contribute to humanity."

This content was produced with the assistance of AI translation services.